

REFERENCES

- Ali, A., Chianese, U., Papulino, C., Toraldo, A., Abakar, M. E., Passaro, E., . . . Benedetti, R. (2022). Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma. *Cancers*, 14(15).
- Aprile, M., Katopodi, V., Leucci, E., & Costa, V. (2020). LncRNAs in Cancer: From garbage to Junk. *Cancers*, 12(11).
- Balas, M. M., & Johnson, A. M. (2018). Exploring the mechanisms behind long noncoding RNAs and cancer. *Non-coding RNA Research*, 3(3), 108-117. <https://doi.org/https://doi.org/10.1016/j.ncrna.2018.03.001>
- Barik, G. K., Sahay, O., Behera, A., Naik, D., & Kalita, B. (2021). Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1876(2), 188612. <https://doi.org/https://doi.org/10.1016/j.bbcan.2021.188612>
- Barth, D. A., Prinz, F., Teppan, J., Jonas, K., Klec, C., & Pichler, M. (2020). Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer. *Noncoding RNA*, 6(3). <https://doi.org/10.3390/ncrna6030027>
- Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., . . . Milella, M. (2020). From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. *Cells*, 9(2). <https://doi.org/10.3390/cells9020309>
- Bin, W., Yuan, C., Qie, Y., & Dang, S. (2023). Long non-coding RNAs and pancreatic cancer: A multifaceted view. *Biomedicine & Pharmacotherapy*, 167, 115601. <https://doi.org/https://doi.org/10.1016/j.biopha.2023.115601>
- Bravo-Vazquez, L. A., Frias-Reid, N., Ramos-Delgado, A. G., Osorio-Perez, S. M., Zlotnik-Chavez, H. R., Pathak, S., . . . Paul, S. (2023). MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications. *Transl Oncol*, 27, 101579. <https://doi.org/10.1016/j.tranon.2022.101579>
- Campisi, J. (2013). Aging, Cellular Senescence, and Cancer. *Annual Review of Physiology*, 75(1), 685-705. <https://doi.org/10.1146/annurev-physiol-030212-183653>
- Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021). Cell death in pancreatic cancer: from pathogenesis to therapy. *Nat Rev Gastroenterol Hepatol*, 18(11), 804-823. <https://doi.org/10.1038/s41575-021-00486-6>
- Chourasia, A. H., Boland, M. L., & Macleod, K. F. (2015). Mitophagy and cancer. *Cancer & Metabolism*, 3(1), 4. <https://doi.org/10.1186/s40170-015-0130-8>
- Cortesi, M., Zanoni, M., Pirini, F., Tumedei, M. M., Ravaioli, S., Rapposelli, I. G., . . . Bravaccini, S. (2022). Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight. *International Journal of Molecular Sciences*, 23(1).
- Dell'Aquila, E., Fulgenzi, C. A. M., Minelli, A., Citarella, F., Stellato, M., Pantano, F., . . . Santini, D. (2020). Prognostic and predictive factors in pancreatic cancer. *Oncotarget*, 11(10), 924-941. <https://doi.org/10.18632/oncotarget.27518>
- Deng, S.-j., Chen, H.-y., Ye, Z., Deng, S.-c., Zhu, S., Zeng, Z., . . . Zhao, G. (2018). Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. *Oncogene*, 37(44), 5811-5828. <https://doi.org/10.1038/s41388-018-0382-1>
- Di Cara, F., Andreoletti, P., Trompier, D., Vejux, A., Bülow, M. H., Sellin, J., . . . Savary, S. (2019). Peroxisomes in Immune Response and Inflammation. *International Journal of Molecular Sciences*, 20(16).
- Drake, L. E., Springer, M. Z., Poole, L. P., Kim, C. J., & Macleod, K. F. (2017). Expanding perspectives on the significance of mitophagy in cancer. *Seminars in Cancer Biology*, 47, 110-124. <https://doi.org/https://doi.org/10.1016/j.semcan.2017.04.008>

- Erickson, L. A., Highsmith Jr, W. E., Fei, P., & Zhang, J. (2015). Targeting the hypoxia pathway to treat pancreatic cancer. *Drug Design, Development and Therapy*, 9(null), 2029-2031. <https://doi.org/10.2147/DDDT.S80888>
- Erickson, L. A., Highsmith, W. E., Fei, P., & Zhang, J. (2015). Targeting the hypoxia pathway to treat pancreatic cancer. *Drug Design, Development and Therapy*, 9, 2029-2031. <https://doi.org/10.2147/DDDT.S80888>
- Fang, Y., & Fullwood, M. J. (2016). Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer. *Genomics, Proteomics & Bioinformatics*, 14(1), 42-54. <https://doi.org/https://doi.org/10.1016/j.gpb.2015.09.006>
- Finn, O. J. (2012). Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. *Annals of Oncology*, 23, viii6-viii9. <https://doi.org/https://doi.org/10.1093/annonc/mds256>
- Furukawa, T. (2015). Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer [Mini Review]. 5. <https://doi.org/10.3389/fonc.2015.00023>
- Ghafouri-Fard, S., Dashti, S., Taheri, M., & Omrani, M. D. (2020). TINCR: An lncRNA with dual functions in the carcinogenesis process. *Non-coding RNA Research*, 5(3), 109-115. <https://doi.org/https://doi.org/10.1016/j.ncrna.2020.06.003>
- Ghafouri-Fard, S., Fathi, M., Zhai, T., Taheri, M., & Dong, P. (2021). LncRNAs: Novel Biomarkers for Pancreatic Cancer. *Biomolecules*, 11(11).
- Gheibi Hayat, S. M., Bianconi, V., Pirro, M., & Sahebkar, A. (2019). Efferocytosis: molecular mechanisms and pathophysiological perspectives. *Immunology & Cell Biology*, 97(2), 124-133. <https://doi.org/https://doi.org/10.1111/imcb.12206>
- Hapke, R. Y., & Haake, S. M. (2020). Hypoxia-induced epithelial to mesenchymal transition in cancer. *Cancer Letters*, 487, 10-20. <https://doi.org/https://doi.org/10.1016/j.canlet.2020.05.012>
- Iriana, S., Ahmed, S., Gong, J., Annamalai, A. A., Tuli, R., & Hendifar, A. E. (2016). Targeting mTOR in Pancreatic Ductal Adenocarcinoma [Mini Review]. 6. <https://doi.org/10.3389/fonc.2016.00099>
- Jiang, M. C., Ni, J. J., Cui, W. Y., Wang, B. Y., & Zhuo, W. (2019). Emerging roles of lncRNA in cancer and therapeutic opportunities. *Am J Cancer Res*, 9(7), 1354-1366.
- Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., . . . Zeng, Z. (2019). Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. *Molecular Cancer*, 18(1), 10. <https://doi.org/10.1186/s12943-018-0928-4>
- Jin, X., Dai, L., Ma, Y., Wang, J., & Liu, Z. (2020). Implications of HIF-1 α in the tumorigenesis and progression of pancreatic cancer. *Cancer Cell International*, 20(1), 273. <https://doi.org/10.1186/s12935-020-01370-0>
- Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019). Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Molecular Cancer*, 18(1), 157. <https://doi.org/10.1186/s12943-019-1089-9>
- Kim, J.-A. (2020). Peroxisome Metabolism in Cancer. *Cells*, 9(7).
- Kulikov, A. V., Luchkina, E. A., Gogvadze, V., & Zhivotovsky, B. (2017). Mitophagy: Link to cancer development and therapy. *Biochemical and Biophysical Research Communications*, 482(3), 432-439. <https://doi.org/https://doi.org/10.1016/j.bbrc.2016.10.088>
- Kunovsky, L., Tesarikova, P., Kala, Z., Kroupa, R., Kysela, P., Dolina, J., & Trna, J. (2018). The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. *Canadian Journal of Gastroenterology and Hepatology*, 2018, 5389820. <https://doi.org/10.1155/2018/5389820>
- Li, H., Wang, X., Wen, C., Huo, Z., Wang, W., Zhan, Q., . . . Shen, B. (2017). Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. *Molecular Cancer*, 16(1), 169. <https://doi.org/10.1186/s12943-017-0738-0>
- Li, J. T., Wang, Y. P., Yin, M., & Lei, Q. Y. (2019). Metabolism remodeling in pancreatic ductal adenocarcinoma. *Cell Stress*, 3(12), 361-368. <https://doi.org/10.15698/cst2019.12.205>

- Lin, Y.-H. (2020). Crosstalk of lncRNA and Cellular Metabolism and Their Regulatory Mechanism in Cancer. *International Journal of Molecular Sciences*, 21(8).
- Liu, S. J., Dang, H. X., Lim, D. A., Feng, F. Y., & Maher, C. A. (2021). Long noncoding RNAs in cancer metastasis. *Nature Reviews Cancer*, 21(7), 446-460. <https://doi.org/10.1038/s41568-021-00353-1>
- Liu, Y., Chen, S., Cai, K., Zheng, D., Zhu, C., Li, L., . . . Sun, C. (2022). Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis. *Cell Death & Disease*, 13(3), 232. <https://doi.org/10.1038/s41419-022-04669-0>
- Lv, Y., & Huang, S. (2019). Role of non-coding RNA in pancreatic cancer (Review). *Oncol Lett*, 18(4), 3963-3973. <https://doi.org/10.3892/ol.2019.10758>
- Majidpoor, J., & Mortezaee, K. (2021). The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. *Clinical Immunology*, 226, 108707. <https://doi.org/https://doi.org/10.1016/j.clim.2021.108707>
- Martinez-Useros, J., & Garcia-Foncillas, J. (2016). Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? *BioMed Research International*, 2016, 4873089. <https://doi.org/10.1155/2016/4873089>
- Matsubara, S., Ding, Q., Miyazaki, Y., Kuwahata, T., Tsukasa, K., & Takao, S. (2013). mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. *Scientific Reports*, 3(1), 3230. <https://doi.org/10.1038/srep03230>
- McCabe, E. M., & Rasmussen, T. P. (2021). lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. *Seminars in Cancer Biology*, 75, 38-48. <https://doi.org/https://doi.org/10.1016/j.semcancer.2020.12.012>
- Mendelsohn, R., Cheung, P., Berger, L., Partridge, E., Lau, K., Datti, A., . . . Dennis, J. W. (2007). Complex N-Glycan and Metabolic Control in Tumor Cells. *Cancer Research*, 67(20), 9771-9780. <https://doi.org/10.1158/0008-5472.CAN-06-4580>
- Mortezaee, K., & Majidpoor, J. (2021). The impact of hypoxia on immune state in cancer. *Life Sciences*, 286, 120057. <https://doi.org/https://doi.org/10.1016/j.lfs.2021.120057>
- Moschovis, D., Gazouli, M., Tzouvala, M., Vezakis, A., & Karamanolis, G. (2017). Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. *Ann Gastroenterol*, 30(6), 622-628. <https://doi.org/10.20524/aog.2017.0185>
- Mucileanu, A., Chira, R., & Mircea, P. A. (2021). PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. *Med Pharm Rep*, 94(4), 402-410. <https://doi.org/10.15386/mpr-2116>
- Nakaoka, K., Ohno, E., Kawabe, N., Kuzuya, T., Funasaka, K., Nakagawa, Y., . . . Hirooka, Y. (2023). Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. *13(2)*, 215. <https://www.mdpi.com/2075-4418/13/2/215>
- Peng, J. F., Zhuang, Y. Y., Huang, F. T., & Zhang, S. N. (2016). Noncoding RNAs and pancreatic cancer. *World J Gastroenterol*, 22(2), 801-814. <https://doi.org/10.3748/wjg.v22.i2.801>
- Porciuncula, A., Hajdu, C., & David, G. (2016). Chapter One - The Dual Role of Senescence in Pancreatic Ductal Adenocarcinoma. In K. D. Tew & P. B. Fisher (Eds.), *Advances in Cancer Research* (Vol. 131, pp. 1-20). Academic Press. <https://doi.org/https://doi.org/10.1016/bs.acr.2016.05.006>
- Prensner, J. R., & Chinnaiyan, A. M. (2011). The Emergence of lncRNAs in Cancer Biology. *Cancer Discovery*, 1(5), 391-407. <https://doi.org/10.1158/2159-8290.CD-11-0209>
- Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021). The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy [Review]. *11*. <https://doi.org/10.3389/fonc.2021.688377>
- Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., . . . Zhao, Y. (2020). Metabolism of pancreatic cancer: paving the way to better anticancer strategies. *Molecular Cancer*, 19(1), 50. <https://doi.org/10.1186/s12943-020-01169-7>

- Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019). PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. *Journal of Cellular Physiology*, 234(10), 16824-16837. <https://doi.org/https://doi.org/10.1002/jcp.28358>
- Schmitt, C. A., Wang, B., & Demaria, M. (2022). Senescence and cancer — role and therapeutic opportunities. *Nature Reviews Clinical Oncology*, 19(10), 619-636. <https://doi.org/10.1038/s41571-022-00668-4>
- Segal, D., & Dostie, J. (2023). The Talented lncRNAs: Meshing into Transcriptional Regulatory Networks in Cancer. *Cancers*, 15(13).
- Shah, V. M., Sheppard, B. C., Sears, R. C., & Alani, A. W. G. (2020). Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. *Cancer Letters*, 492, 63-70. <https://doi.org/https://doi.org/10.1016/j.canlet.2020.07.041>
- Song, J., Xu, Q., Zhang, H., Yin, X., Zhu, C., Zhao, K., & Zhu, J. (2018). Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma. *Journal of Cellular Biochemistry*, 119(6), 4559-4569. <https://doi.org/https://doi.org/10.1002/jcb.26598>
- Sturm, N., Ettrich, T. J., & Perkhofer, L. (2022). The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. *Cancers (Basel)*, 14(1). <https://doi.org/10.3390/cancers14010217>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209-249. <https://doi.org/https://doi.org/10.3322/caac.21660>
- Tam, S. Y., Wu, V. W. C., & Law, H. K. W. (2020). Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1 α and Beyond [Review]. 10. <https://doi.org/10.3389/fonc.2020.00486>
- Tan, Z., Xu, J., Zhang, B., Shi, S., Yu, X., & Liang, C. (2020). Hypoxia: a barricade to conquer the pancreatic cancer. *Cellular and Molecular Life Sciences*, 77(16), 3077-3083. <https://doi.org/10.1007/s00018-019-03444-3>
- Tímár, J., Sebestyén, A., Kopper, L., & Dankó, T. (2021). Hypoxia Signaling in Cancer: From Basics to Clinical Practice [Review]. 27. <https://doi.org/10.3389/pore.2021.1609802>
- Truong, L.-H., & Pauklin, S. (2021). Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. *Cancers*, 13(19).
- Ushio, J., Kanno, A., Ikeda, E., Ando, K., Nagai, H., Miwata, T., . . . Yamamoto, H. (2021). Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. *Diagnostics*, 11(3).
- Wang, S., Li, Y., Xing, C., Ding, C., Zhang, H., Chen, L., . . . Zhao, Y. (2020). Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. *Am J Cancer Res*, 10(7), 1937-1953.
- Werfel, T. A., & Cook, R. S. (2018). Efferocytosis in the tumor microenvironment. *Seminars in Immunopathology*, 40(6), 545-554. <https://doi.org/10.1007/s00281-018-0698-5>
- Williams, G. H., & Stoeber, K. (2012). The cell cycle and cancer. *The Journal of Pathology*, 226(2), 352-364. <https://doi.org/https://doi.org/10.1002/path.3022>
- Wong, C. H., Lou, U. K., Fung, F. K.-C., Tong, J. H. M., Zhang, C.-h., To, K.-F., . . . Chen, Y. (2022). CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. *Molecular Cancer*, 21(1), 10. <https://doi.org/10.1186/s12943-021-01481-w>
- Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022). Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. *Journal of Hematology & Oncology*, 15(1), 77. <https://doi.org/10.1186/s13045-022-01292-6>
- Xiao, Z.-D., Zhuang, L., & Gan, B. (2016). Long non-coding RNAs in cancer metabolism. *BioEssays*, 38(10), 991-996. <https://doi.org/https://doi.org/10.1002/bies.201600110>
- Xiong, Q., Liu, B., Ding, M., Zhou, J., Yang, C., & Chen, Y. (2020). Hypoxia and cancer related pathology. *Cancer Letters*, 486, 1-7. <https://doi.org/https://doi.org/10.1016/j.canlet.2020.05.002>

- Yamasaki, A., Yanai, K., & Onishi, H. (2020). Hypoxia and pancreatic ductal adenocarcinoma. *Cancer Letters*, 484, 9-15. <https://doi.org/https://doi.org/10.1016/j.canlet.2020.04.018>
- Yang, G., Lu, X., & Yuan, L. (2014). LncRNA: A link between RNA and cancer. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*, 1839(11), 1097-1109. <https://doi.org/https://doi.org/10.1016/j.bbagr.2014.08.012>
- Ye, L.-Y., Zhang, Q., Bai, X.-L., Pankaj, P., Hu, Q.-D., & Liang, T.-B. (2014). Hypoxia-inducible factor 1 α expression and its clinical significance in pancreatic cancer: A meta-analysis. *Pancreatology*, 14(5), 391-397. <https://doi.org/https://doi.org/10.1016/j.pan.2014.06.008>
- You, L., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimova, E., . . . Kuca, K. (2021). The role of hypoxia-inducible factor 1 in tumor immune evasion. *Medicinal Research Reviews*, 41(3), 1622-1643. <https://doi.org/https://doi.org/10.1002/med.21771>
- Yuen, A., & Díaz, B. (2014). The impact of hypoxia in pancreatic cancer invasion and metastasis. *Hypoxia*, 2(null), 91-106. <https://doi.org/10.2147/HP.S52636>
- Yun, C. W., & Lee, S. H. (2018). The Roles of Autophagy in Cancer. *International Journal of Molecular Sciences*, 19(11).
- Zhang, Q., Han, Z., Zhu, Y., Chen, J., & Li, W. (2021). Role of hypoxia inducible factor-1 in cancer stem cells (Review). *Mol Med Rep*, 23(1), 17. <https://doi.org/10.3892/mmr.2020.11655>
- Zheng, Y., Fang, Y. C., & Li, J. (2019). PD-L1 expression levels on tumor cells affect their immunosuppressive activity. *Oncol Lett*, 18(5), 5399-5407. <https://doi.org/10.3892/ol.2019.10903>